All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Durvalumab Plus FLOT Prolongs OS vs FLOT Alone in Gastric/GEJ Adenocarcinoma

October 17th 2025

The addition of durvalumab to FLOT prolonged overall survival vs FLOT alone in resectable gastric/gastroesophageal junction adenocarcinoma.

Sevabertinib Yields Robust Responses in HER2-Mutant Advanced NSCLC

October 17th 2025

Sevabertinib monotherapy led to robust and durable responses in first-line and pretreated patients with HER2-mutant advanced non–small cell lung cancer.

Abemaciclib Plus Endocrine Therapy Provides OS Benefit in HR+/HER2-Negative Breast Cancer

October 17th 2025

The addition of adjuvant abemaciclib to endocrine therapy provided an OS benefit vs endocrine therapy alone in hormone receptor–positive breast cancer.

First-Line Alectinib Yields Clinically Meaningful OS Benefit in Advanced ALK+ NSCLC

October 17th 2025

First-line alectinib produced a clinically meaningful overall survival benefit in advanced ALK-positive non–small cell lung cancer.

Combining Durvalumab With BCG Yields Significant DFS Benefit vs BCG Alone in BCG-Naive NMIBC

October 17th 2025

Durvalumab plus BCG induction and maintenance therapy yielded clinically meaningful improvement in DFS vs BCG induction and maintenance therapy alone in BCG-naive, high-risk NMIBC.

Zongertinib Displays Activity in Frontline HER2-Mutated NSCLC

October 17th 2025

Zongertinib was effective for the first-line treatment of patients with treatment-naive HER2-mutated NSCLC.

Asciminib Receives Positive CHMP Opinion for Ph+ CP-CML

October 17th 2025

The EMA’s CHMP has recommended the approval of asciminib for Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Lenvatinib Plus Pembrolizumab and Chemotherapy Fails to Improve OS in Advanced ESCC

October 17th 2025

First-line treatment with lenvatinib, pembrolizumab, and chemotherapy did not improve OS vs chemoimmunotherapy in patients with advanced ESCC.

Adjuvant Cemiplimab Recommended for European Approval in CSCC

October 17th 2025

The EMA’s CHMP has recommended the approval of adjuvant cemiplimab in CSCC at high risk of recurrence after surgery and radiation

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected MIUC

October 17th 2025

Five year follow up results from CheckMate 274 support adjuvant nivolumab as a standard of care for high-risk muscle-invasive urothelial carcinoma.

Mayo Clinic Researchers Discover ‘Traffic Controller’ Protein That Protects DNA, and May Help Kill Cancer Cells

October 17th 2025

Mayo Clinic researchers have identified a protein that acts like a traffic controller for DNA, preventing damage during cell division.

Axi-Cel Advances Signal Shifts Toward Earlier-Line Applications in LBCL

October 16th 2025

Taylor Brooks, MD, discusses the effects of CAR T-cell therapy on LBCL management and the efficacy of axi-cel for patients with relapsed/refractory LBCL.

JAK Inhibitors Persist, While Novel Agents Aim for Disease Modification in Myelofibrosis

October 16th 2025

Aaron Gerds, MD, MS, discusses the clinical applications of each of the FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Novel Immunotherapy Combination Destroys Colorectal Liver Metastases

October 16th 2025

Researchers from UCSF discovered that a combination of immunotherapies can reprogram the immune environment of colon cancer tumors in the liver.

Teclistamab Plus Daratumumab Boosts Survival in R/R Myeloma

October 16th 2025

Teclistamab plus daratumumab improved progression-free and overall survival in relapsed/refractory multiple myeloma after 1 to 3 lines of therapy.

Pembrolizumab Plus Chemo With or Without Bevacizumab Improves OS in Platinum-Resistant Ovarian Cancer

October 16th 2025

Pembrolizumab plus chemotherapy with or without bevacizumab improved overall survival in platinum-resistant ovarian cancer.

Study Shows ChatGPT Struggles With Patient-Specific Queries, Novel Therapies in Hematologic Malignancies

October 16th 2025

A study found ChatGPT 3.5 was more likely to give incomplete or inaccurate answers to specific hematologic malignancy queries vs general questions.

FDA Grants Orphan Drug Designation to MNV-201 for Myelodysplastic Syndrome

October 16th 2025

MNV-201 has received orphan drug designation from the FDA for use in myelodysplastic syndrome.

Toripalimab Plus CCRT Generates 100% ORR, But Safety Concerns Warrant Additional Research in Locally Advanced Cervical Cancer

October 16th 2025

Toripalimab plus CCRT produced a 100% ORR in locally advanced cervical cancer, although the regimen was associated with radiation-related AEs and irAEs.

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma

October 15th 2025

Acalabrutinib plus lenalidomide and rituximab displayed activity and had a tolerable safety profile in first-line follicular lymphoma.